Phar Vision Advisers, LLC Delcath Systems, Inc. Call Options Transaction History
Phar Vision Advisers, LLC
- $118 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DCTH
# of Institutions
95Shares Held
11MCall Options Held
144KPut Options Held
57.4K-
Vivo Capital, LLC Palo Alto, CA1.71MShares$26.2 Million3.93% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.39MShares$21.3 Million6.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.22MShares$18.8 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT801KShares$12.3 Million0.66% of portfolio
-
Gilder Gagnon Howe & CO LLC New York, NY612KShares$9.39 Million0.08% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $132M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...